Drug utilization pattern and cost analysis of anticancer drugs among cancer patients attending a tertiary cancer hospital in Nepal: A cross-sectional study
This cross-sectional study at a tertiary cancer hospital in Nepal reveals that while anticancer drugs are almost universally prescribed as generics, their actual costs vary widely among patients and are not reliably predicted by demographic or prescribing factors, highlighting a need for improved adherence to the national essential medicines list and closer monitoring of drug pricing.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of a preprint that has not been peer-reviewed. It is not medical advice. Do not make health decisions based on this content. Read full disclaimer
Imagine you are walking into a giant, bustling pharmacy. In this pharmacy, doctors are handing out special, powerful potions to fight invisible invaders inside the body. These potions are called chemotherapy drugs. But here's the tricky part: these potions are complicated, they come in many different flavors (brands), and they can be very expensive. Sometimes, the price tag on the bottle is huge, but the actual amount you pay is different. To make sure everyone is getting the right potion without wasting money or getting sick from too many extra ingredients, scientists use a set of "checklist rules." One famous checklist is like a "Hall of Fame" for medicines, called the Essential Medicines List. It's a list of the most important, proven drugs that every country should have. Another rule is to use the generic name of the drug (like calling a tissue "facial tissue" instead of a specific brand name) to save money. This paper is a detective story about how these rules are being followed in a specific cancer hospital in Nepal, and how much the patients are actually paying for their medicine.
The researchers in this study decided to play detective at the Bhaktapur Cancer Hospital in Nepal. They looked at the medical records of 151 patients who were there to get their chemotherapy. They wanted to answer three big questions: What drugs are the doctors prescribing? Are they following the "Hall of Fame" rules? And most importantly, how much does this treatment actually cost the patients?
First, they looked at the "shopping cart" of each patient. They found that, on average, a patient received about 10.56 different drugs in total. However, only about 1.72 of those were the main "anti-cancer" weapons; the rest were helpers, like drugs to stop nausea or protect the body. The good news is that the doctors were almost perfect at using generic names. In fact, 99.85% of the drugs were prescribed by their generic name, which is like always buying the store-brand cereal instead of the fancy box. This is a huge win for saving money.
However, when they checked if the drugs were on the "Hall of Fame" list (the National Essential Medicines List), the score wasn't perfect. On average, only about 63% to 67% of the drugs were on that official list. This means that for every three or four drugs a patient got, one or two might be "off-menu" or not on the government's preferred list. The study suggests this isn't necessarily because the doctors are doing something wrong, but maybe because the list is a bit too short for all the different types of cancer patients have.
Then came the money part, and this is where things got interesting. The researchers looked at the "Maximum Retail Price" (the highest price a shop could charge) versus the "Actual Cost" (what the patient actually paid). They found a massive gap. The average maximum price was NPR 38,803.22, but the average actual cost the patients paid was only NPR 15,245.28. It's like seeing a toy listed for $40 in a catalog, but when you go to the store, you only pay $15 because of a secret sale or a discount. The study also looked at the Health Insurance Board rate, which was an average of NPR 25,852.36, showing that insurance helps cover some of the difference, but patients still pay a chunk out of their own pockets.
The team tried to figure out why some patients paid more than others. They asked: "Is it because the patient is a boy or a girl? Is it because they are older? Is it because they have a different type of cancer?" In the beginning, they thought maybe being a male patient meant you paid more, but when they looked at all the factors together, that idea disappeared. In the end, the study found that none of the things they checked—like age, gender, how many drugs were used, or which cancer type—could reliably explain why one patient's bill was higher than another's. The cost varied wildly, like a rollercoaster, but the reasons for the ups and downs remained a mystery.
So, what is the final verdict? The study suggests that while doctors in this hospital are excellent at using generic names to save money, they are only partially following the official "Essential Medicines" list. The cost of treatment is a rollercoaster that varies a lot from person to person, but the study couldn't find a simple reason why. The authors suggest that to help patients, the hospital and the government need to look closer at why prices jump around so much and try to make sure the official list of medicines matches what doctors actually need to use. It's a reminder that even when we follow some rules, there are still hidden costs and puzzles to solve in the fight against cancer.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.